ARWR — Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Net Income: $30.8 million, or $0.22 per share, compared to a net loss of $173.1 million, or $1.39 per share, in Q1 2025.
• Revenue: $264 million, primarily driven by collaboration agreements with Sarepta and Novartis, including $229 million from Sarepta and $34 million from Novartis.
• Operating Expenses: Totaled approximately $223 million, up from $164 million in the prior year, driven by increased R&D and SG&A expenses.
• Cash and Investments: $917 million as of December 31, 2025, excluding recent financing transactions and milestone payments expected shortly.

2. Strategic Updates and Business Highlights:

• Product Launch: Arrowhead launched REDEMPLO, its first commercial product approved by the FDA for treating familial chylomicronemia syndrome (FCS), with positive early prescription trends.
• Regulatory Approvals: REDEMPLO also received approvals in Canada and China, with potential launches in select EU countries anticipated later in 2026.
• Pipeline Development: Progress in cardiometabolic and CNS programs, including ongoing Phase III studies for plozasiran and early promising data from obesity treatments ARO-INHBE and ARO-ALK7.
• Collaborations: Secured a $200 million upfront payment from Novartis through a licensing agreement and received a $200 million milestone payment from Sarepta.

3. Forward Guidance and Outlook:

• Anticipated key events for 2026 include:
  • Continued commercial sales growth for REDEMPLO.
  • Q3 2026 readouts from Phase III studies for plozasiran targeting severe hypertriglyceridemia (SHTG).
  • Additional data from obesity programs and CNS pipeline candidates expected later in the year.
• The company aims to become cash flow positive through independent and partner launches.

4. Bad News, Challenges, or Points of Concern:

• Increased Expenses: Operating expenses rose significantly, which may pressure profitability despite revenue growth.
• Market Competition: The obesity treatment landscape is competitive, with pricing pressures from existing therapies like tirzepatide and new entrants.
• Regulatory Risks: Future approvals and market acceptance for plozasiran and other pipeline candidates remain uncertain, particularly in competitive therapeutic areas.
• Patient Onboarding: Early data on patient uptake for REDEMPLO is limited, and the company cautioned against overinterpreting initial prescription trends.

5. Notable Q&A Insights:

• Patient Dynamics: The majority of early prescriptions for REDEMPLO come from APOC3-naive patients, with a balanced split between those switching from other therapies and those transitioning from expanded access programs.
• FDA Discussions: Plans to engage with the FDA regarding the development path for obesity treatments are expected mid-2026.
• Pricing Strategy: Discussions around pricing for obesity treatments are premature, with the company focusing on clinical efficacy before determining pricing models.
• Event Rates in Trials: While the company is observing acute pancreatitis events in ongoing trials, specific data was not disclosed, and comparisons to prior studies were noted as rational but not definitive.

Overall, Arrowhead Pharmaceuticals demonstrated strong financial performance and strategic progress in Q1 2026, with a focus on expanding its product offerings and pipeline while navigating potential challenges in competitive markets and regulatory landscapes.